Redeye gives its view on CLS' Q3’21 report as well as yesterday’s news regarding the relaunch of its sterile disposable products in the US. We maintain our positive long-term view and reiterate our Base Case.
ANNONS
Redeye gives its view on CLS' Q3’21 report as well as yesterday’s news regarding the relaunch of its sterile disposable products in the US. We maintain our positive long-term view and reiterate our Base Case.
